Hemophilia B Clinical Trials 2024: EMA, PDMA, FDA Approvals, Medication, Therapies, Mechanism of Action, Route of Administration, and companies by DelveInsight | Shanghai Vitalgen BioPharma, Belief BioMed, TiumBio, Jiangsu Gensciences, Centessa Pharma, Pf

(Albany, USA) As per DelveInsight's assessment, globally, about 15+ key pharma and biotech companies are working on 20+ pipeline drugs in the Hemophilia B therapeutics landscape based on different Routes of Administration (ROA), Mechanism of Action (MOA), and molecule types. Several of the therapies are in the advanced stages of clinical development and are expected to launch in the coming years.

"Hemophilia B Pipeline Insight 2024" report by DelveInsight provides a comprehensive analysis of the ongoing clinical development activities and growth prospects across the Hemophilia B Therapeutics Market.
The report provides a detailed description of the Hemophilia B drugs, including the mechanism of action, type, stage, route of administration, molecule type, clinical studies, inactive pipeline products, and NDA approvals (if any). The report also covers commercial and clinical activities of the pipeline products from the pre-clinical developmental phase to the marketed stage. Additionally, it presents the ongoing developments in the therapeutics segment, including collaborations, licensing, mergers & acquisitions (M&A), funding, designations, and other product-related details.

Get a Detailed Overview of the Hemophilia B Clinical Trial Activities and Regulatory Developments in the domain @ https://www.delveinsight.com/report-store/hemophilia-b-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Hemophilia B Therapeutics Analysis
Approximately 15+ notable companies are actively engaged in developing therapies for Hemophilia B. Among these, Belief Biomed stands out for advancing its Hemophilia B drug candidates to the most advanced stage of clinical trials, specifically Phase III. This phase represents a crucial stage in the drug development process, where the efficacy and safety of the treatment are rigorously assessed in a larger patient population. Belief Biomed's progress to Phase III underscores the potential significance of its therapeutic approach in addressing the challenges posed by Hemophilia B, reflecting dedication and progress within the field of hematology and rare diseases.

Recent developments in Hemophilia B Pipeline:
• In May 2024, Novo Nordisk A/S has announced results of a Multi-centre, Open-label Trial Evaluating Efficacy, Safety and Pharmacokinetics of Nonacog Beta Pegol When Used for Treatment and Prophylaxis of Bleeding Episodes in Chinese Patients With Haemophilia B.
• In May 2024, ApcinteX Ltd has announced results of a Global, Open-label, Adaptive Design Study to Investigate the Efficacy and Safety of SerpinPC in Subjects With Severe Hemophilia A or Moderately Severe to Severe Hemophilia B

Learn More about the Clinical and Commercial Development Activities in the Hemophilia B Therapeutics Domain @
https://www.delveinsight.com/report-store/hemophilia-b-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Hemophilia B Companies in the Therapeutics Market Include:
• Shanghai Vitalgen BioPharma
• Belief BioMed
• TiumBio
• Jiangsu Gensciences
• Centessa Pharmaceuticals
• Pfizer
• OPKO Health
• Bayer
• Takeda
• Sanofi
And Many Others

Emerging and Marketed Hemophilia B Therapies Covered in the Report Include:
• BBM-H901: Belief Biomed
• TU7710: TiumBio
• Concizumab: Novo Nordisk
• Fitusiran: Sanofi/Alnylam Pharmaceuticals
• Etranacogene dezaparvovec (AMT-061): CSL Behring/uniQure
• Fidanacogene elaparvovec (SPK-9001/PF-06838435): Pfizer/Spark Therapeutics
• AMT-060 (AAV5-hFIX): UniQure
• Verbrinacogene setparvovec (FLT-180a): Freeline Therapeutics
And Many More

Get an in-depth Assessment of the Emerging Therapies and Hemophilia B Companies Actively Working in the Market @
https://www.delveinsight.com/sample-request/hemophilia-b-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

The Report Covers the Emerging Hemophilia B Therapies Under Different Phases of Clinical Development Like -
• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I)
• Pre-clinical and Discovery stage candidates
• Discontinued and inactive candidates

Route of Administration
Hemophilia B pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
• Oral
• Intravenous
• Subcutaneous
• Parenteral
• Topical

Molecule Type
Products have been categorized under various Molecule types such as
• Recombinant fusion proteins
• Small molecule
• Monoclonal antibody
• Peptide
• Polymer
• Gene therapy

Request for Sample PDF to Understand More About the Hemophilia B Treatment Outlook and Future Perspectives @
https://www.delveinsight.com/sample-request/hemophilia-b-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Hemophilia B Pipeline Analysis
The report provides insights into:
• The report provides detailed insights into the key companies that are developing Hemophilia B therapies.
• The report also evaluates different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Hemophilia B treatment.
• It analyzes the key companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• It navigates the emerging Hemophilia B drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement, and financing details for future advancement in the Hemophilia B treatment market.

Table of Content
1. Report Introduction
2. Executive Summary
3. Hemophilia B Current Treatment Patterns
4. Hemophilia B - DelveInsight's Analytical Perspective
5. Therapeutic Assessment
6. Hemophilia B Late-Stage Products (Phase-III)
7. Hemophilia B Mid-Stage Products (Phase-II)
8. Early Stage Products (Phase-I)
9. Pre-clinical Products and Discovery Stage Products
10. Inactive Products
11. Dormant Products
12. Hemophilia B Discontinued Products
13. Hemophilia B Product Profiles
14. Hemophilia B Companies
15. Hemophilia B Drugs
16. Dormant and Discontinued Products
17. Hemophilia B Unmet Needs
18. Hemophilia B Future Perspectives
19. Hemophilia B Analyst Review
20. Appendix
21. Report Methodology

Get Detailed Insights About the Reports Offerings @
https://www.delveinsight.com/sample-request/hemophilia-b-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Trending Reports:
• Esophageal Squamous Carcinoma Market: https://www.delveinsight.com/report-store/esophageal-cancer-market
• Failed Back Surgery Syndrome Market: https://www.delveinsight.com/report-store/failed-back-surgery-syndrome-market
• Familial Hypercholesterolemia Market: https://www.delveinsight.com/report-store/homozygous-familial-hypercholesterolemia-market
• Familial Lipoprotein Lipase Deficiency Pipeline: https://www.delveinsight.com/report-store/familial-lipoprotein-lipase-deficiency-pipeline-insight
• Fibrocystic Breast Condition Market: https://www.delveinsight.com/report-store/fibrocystic-breast-condition-market
• Fucosidosis Market: https://www.delveinsight.com/report-store/fucosidosis-market
• Glycogen Storage Disease Market: https://www.delveinsight.com/report-store/glycogen-storage-disease-market
• Head And Neck Cancer Market: https://www.delveinsight.com/report-store/head-and-neck-cancer-hnc-market
• Hemorrhagic Cystitis Market: https://www.delveinsight.com/report-store/hemorrhagic-cystitis-market
• Hepatic Encephalopathy Epidemiology Forecast: https://www.delveinsight.com/report-store/hepatic-encephalopathy-epidemiology-forecast
• Hepatic Encephalopathy Market: https://www.delveinsight.com/report-store/hepatic-encephalopathy-market
• Her2-negative Breast Cancer Market: https://www.delveinsight.com/report-store/hr-positive-her2-negative-breast-cancer-market-insights
• Her2-positive Early Breast Cancer Market: https://www.delveinsight.com/report-store/metastatic-her2-positive-breast-cancer-market
• Hiatal Hernia Market: https://www.delveinsight.com/report-store/hiatal-hernia-market
• Hospital-acquired And Ventilator-associated Bacterial Pneumonia Habp/vabp Market: https://www.delveinsight.com/report-store/hospital-acquired-and-ventilator-associated-bacterial-pneumonia-market
• Hpv16+ Cancer Market: https://www.delveinsight.com/report-store/human-papillomavirus-16-positive-hpv16-cancers-market
• Hypereosinophilic Syndrome Market: https://www.delveinsight.com/report-store/hypereosinophilic-syndrome-market
• Hyperkalemia Market: https://www.delveinsight.com/report-store/hyperkalemia-market
• Hypertrophic Cardiomyopathy Market: https://www.delveinsight.com/report-store/hypertrophic-cardiomyopathy-market
• Immunologic Deficiency Syndrome Market: https://www.delveinsight.com/report-store/immunologic-deficiency-syndrome-market
• Implantable Infusion Pump Market: https://www.delveinsight.com/report-store/implantable-infusion-pumps-market
• Implantable Infusion Pumps Market: https://www.delveinsight.com/report-store/implantable-infusion-pumps-market
• Intracranial Arterial Diseases Market: https://www.delveinsight.com/report-store/intracranial-arterial-diseases-market
• Lamellar Icthyosis Market: https://www.delveinsight.com/report-store/lamellar-ichthyosis-market

Contact Us:
Ankit Nigam
Manager Marketing
info@delveinsight.com
+14699457679
https://www.delveinsight.com/consulting/primary-research-services
Case study: https://www.delveinsight.com/case-study/esmo-conference-coverage

About DelveInsight
DelveInsight is a leading Life Science market research and business consulting company recognized for its off-the-shelf syndicated market research reports and customized solutions to firms in the healthcare sector.

This release was published on openPR.